Literature DB >> 23645474

Bloodstream infections in patients with or without cancer in a large community hospital.

M M E M Bos1, L S Smeets, I Dumay, E de Jonge.   

Abstract

PURPOSE: Cancer is associated with an increased risk of acquiring bloodstream infection (BSIs). Most knowledge on pathogens and outcome are derived from specialised cancer centres. We here sought to compare causative micro-organisms in BSIs in patients with or without cancer in a 600-bed teaching community hospital.
METHODS: We analysed all positive blood cultures from adult patients between January 2005 and January 2011.
RESULTS: A total of 4,918 episodes of BSI occurred in 2,891 patients, of whom 13.4% had a diagnosis of cancer (85.5% with a solid tumour). In both patient groups, Gram-positive isolates were more prevalent (58.7 and 61.4% in patients with and without cancer, respectively) than Gram-negative isolates (31.8 and 32.3%, respectively). Amongst Gram-positive organisms, coagulase-negative staphylococci, Staphylococcus aureus and enterococci were the most frequently isolated in both patient groups; in cancer patients, twice as many BSIs were caused by Enterococcus faecalis and E. faecium. Amongst Gram-negative organisms, Escherichia coli was the most common isolate; in cancer patients, twice as many BSIs were caused by Pseudomonas aeruginosa and Enterobacter cloacae. Yeasts were grown from 3.0% of blood cultures from cancer patients compared to 1.5% of cultures from non-cancer patients. Cancer patients had a 90-day mortality of 35.8% following BSI compared to 23.5% in patients without cancer.
CONCLUSION: These data demonstrate distinct BSI pathogens and impaired outcomes in patients with cancer in the setting of a large community teaching hospital.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23645474     DOI: 10.1007/s15010-013-0468-1

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  28 in total

1.  Analysis of 553 episodes of monomicrobial bacteraemia in cancer patients: any association between risk factors and outcome to particular pathogen?

Authors:  S Spanik; E Kukuckova; P Pichna; S Grausova; I Krupova; V Rusnakova; K Kralovicova; A Krchnakova; M Mrazova; J Lacka; P Koren; K Stopkova; J Nogova; A Demitrovicova; L Helpianska; V Krcmery
Journal:  Support Care Cancer       Date:  1997-07       Impact factor: 3.603

2.  Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution.

Authors:  E González-Barca; A Fernández-Sevilla; J Carratalá; A Grañena; F Gudiol
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-04       Impact factor: 3.267

Review 3.  Infectious morbidity in critically ill patients with cancer.

Authors:  A Safdar; D Armstrong
Journal:  Crit Care Clin       Date:  2001-07       Impact factor: 3.598

4.  Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality.

Authors:  D Pittet; D Tarara; R P Wenzel
Journal:  JAMA       Date:  1994-05-25       Impact factor: 56.272

5.  International study of the prevalence and outcomes of infection in intensive care units.

Authors:  Jean-Louis Vincent; Jordi Rello; John Marshall; Eliezer Silva; Antonio Anzueto; Claude D Martin; Rui Moreno; Jeffrey Lipman; Charles Gomersall; Yasser Sakr; Konrad Reinhart
Journal:  JAMA       Date:  2009-12-02       Impact factor: 56.272

6.  Predictors of mortality in bacteremic cancer patients: retrospective analysis of 64 deaths occurring among 262 bacteremic episodes.

Authors:  S Spanik; J Sufliarsky; J Mardiak; D Sorkovska; J Trupl; A Kunova; E Kukuckova; V Rusnakova; A Demitrovicova; P Pichna; I Krupova; K Kralovicova; F Mateićka; D West; V Krcmery
Journal:  Support Care Cancer       Date:  1998-05       Impact factor: 3.603

7.  Investigation of a nosocomial outbreak by alginate-producing pan-antibiotic-resistant Pseudomonas aeruginosa.

Authors:  Yusuf Yakupogullari; Baris Otlu; Muruvvet Dogukan; Canan Gursoy; Ebru Korkmaz; Ahmet Kizirgil; Mehmet Ozden; Riza Durmaz
Journal:  Am J Infect Control       Date:  2008-12       Impact factor: 2.918

8.  Bloodstream infections in patients with solid tumors: associated factors, microbial spectrum and outcome.

Authors:  M Anatoliotaki; V Valatas; E Mantadakis; H Apostolakou; D Mavroudis; V Georgoulias; K V Rolston; D P Kontoyiannis; E Galanakis; G Samonis
Journal:  Infection       Date:  2004-04       Impact factor: 3.553

9.  Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006.

Authors:  Kevin B Laupland; Terry Ross; Daniel B Gregson
Journal:  J Infect Dis       Date:  2008-08-01       Impact factor: 5.226

10.  Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia.

Authors:  Thierry Calandra; J Klastersky; H Gaya; M P Glauser; F Meunier; S H Zinner
Journal:  N Engl J Med       Date:  1987-12-31       Impact factor: 91.245

View more
  15 in total

1.  Sepsis in standard care: patients' characteristics, effectiveness of antimicrobial therapy and patient outcome--a cohort study.

Authors:  Franz Ratzinger; Katharina Eichbichler; Michael Schuardt; Irene Tsirkinidou; Dieter Mitteregger; Helmuth Haslacher; Thomas Perkmann; Klaus G Schmetterer; Georg Doffner; Heinz Burgmann
Journal:  Infection       Date:  2015-04-04       Impact factor: 3.553

2.  The importance of mobile phones in the possible transmission of bacterial infections in the community.

Authors:  A Bhoonderowa; S Gookool; S D Biranjia-Hurdoyal
Journal:  J Community Health       Date:  2014-10

Review 3.  Developments for improved diagnosis of bacterial bloodstream infections.

Authors:  A J M Loonen; P F G Wolffs; C A Bruggeman; A J C van den Brule
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-22       Impact factor: 3.267

4.  Efficacy of daptomycin lock therapy in the treatment of bloodstream infections related to long-term catheter.

Authors:  P Tatarelli; A Parisini; V Del Bono; M Mikulska; C Viscoli
Journal:  Infection       Date:  2014-08-12       Impact factor: 3.553

5.  Clinical prognostic factors for time to positivity in cancer patients with bloodstream infections.

Authors:  Qing Zhang; Ding Li; Changsen Bai; Wenfang Zhang; Shan Zheng; Peng Zhang; Sihe Zhang
Journal:  Infection       Date:  2016-03-18       Impact factor: 3.553

Review 6.  Bloodstream infections in patients with solid tumors.

Authors:  Carlota Gudiol; José María Aguado; Jordi Carratalà
Journal:  Virulence       Date:  2016-01-19       Impact factor: 5.882

Review 7.  Bloodstream infections in neutropenic cancer patients: A practical update.

Authors:  Giulia Gustinetti; Malgorzata Mikulska
Journal:  Virulence       Date:  2016-04-02       Impact factor: 5.882

8.  Descriptive epidemiology of Escherichia coli bacteraemia in England, April 2012 to March 2014.

Authors:  Sabine Bou-Antoun; John Davies; Rebecca Guy; Alan P Johnson; Elizabeth A Sheridan; Russell J Hope
Journal:  Euro Surveill       Date:  2016-09-01

Review 9.  Pathogenesis of intestinal Pseudomonas aeruginosa infection in patients with cancer.

Authors:  Panayiota Markou; Yiorgos Apidianakis
Journal:  Front Cell Infect Microbiol       Date:  2014-01-07       Impact factor: 5.293

Review 10.  Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO).

Authors:  Olaf Penack; Carolin Becker; Dieter Buchheidt; Maximilian Christopeit; Michael Kiehl; Marie von Lilienfeld-Toal; Marcus Hentrich; Marc Reinwald; Hans Salwender; Enrico Schalk; Martin Schmidt-Hieber; Thomas Weber; Helmut Ostermann
Journal:  Ann Hematol       Date:  2014-04-29       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.